

Alukon®

montelukast

Indications for different forms from the age of 6 months to adults:

- **treatment of chronic inflammation in asthma**
- **prevention of asthma symptoms during the day and at night**
- **relieve symptoms of allergic rhinitis**

In patients:

- who are not adequately controlled with their current treatment need additional treatment
- who are unable to properly use the inhaled route to administer corticosteroids
- who suffer from exercise-induced asthma

Long-term treatment for asthma, even from level 1 for patients who cannot / do not want to use inhaled corticosteroids or who experience intolerable side effects from inhaled corticosteroids, such as persistent hoarseness and those with associated allergic rhinitis.

HOW TO TAKE ALUKON®?	
DAILY DOSE: preferably administered in the evening	
6 months to 5 years old	1 sachet of 4 mg granules
6 to 14 years old	1 chewable tablet 4 mg
above age 14 and adults	1 tablet of 10 mg

- 24-hour anti-leukotriene action in a single daily dose
- can be taken with or without food
- rapid relief and efficacy as from day one
- proven bronchodilatory and anti-inflammatory effects in asthma and allergic rhinitis
- good tolerance - good compliance
- can be used in pregnant women
- reduction in corticosteroids and beta-2 antagonists: an excellent alternative in asthma

Never use montelukast to treat acute asthma attacks.

Alukon®

montelukast



REDUCE THE SYMPTOMS OF ASTHMA AND ALLERGIC RHINITIS



LEUKOTRIENE RECEPTOR ANTAGONIST

**GIVE YOUR PATIENTS
THE MEANS TO BREATHE
FREELY AND EASILY**

FIGHT SYMPTOMS OF ALLERGIC RHINITIS

For information about our
other products, please visit
www.dafrapharma.com and
create your personal account.



SCAN



Setting the standard

www.dafrapharma.com

Alukon®

montelukast

80% of asthma patients have allergic rhinitis.

Patients with allergic rhinitis are three times more likely to develop asthma.

Asthma and (allergic) rhinitis:
two inflammatory conditions
linked by a common airway and
a common inflammatory mediator,
leukotrienes.

*Symptoms triggered by leukotrienes:
major causes of reduced quality of life*

Asthma	Allergic rhinitis
<ul style="list-style-type: none">• continuous respiratory discomfort• constriction (smooth muscle contraction) and oedema in the bronchi - breathing problems• inflammation and• hypersecretion of mucus in the bronchi• cough, wheezing and chest tightness	<ul style="list-style-type: none">• rhinorrhea• congestion (immediate and long-term)• sneezing• itching (nasal)

Leukotrienes are common mediators of upper and lower respiratory diseases.


**By blocking the leukotriene pathway,
ALUKON® improves asthma symptoms,
contributes to the control of asthma
and improves symptoms of allergic rhinitis.**

For the full SMPC, please scan this QR code.




Improve the quality of life of your asthma patients Proven efficacy for asthma symptoms and allergic rhinitis

asthmatic cough - wheezing - chest tightness - dyspnea - nighttime awakening
% of symptom-free asthmatic patients (after 6 weeks of treatment)



Adapted from IMAJ 2008;10:287–291

Montelukast monotherapy in patients with persistent asthma provides very satisfactory results for patients, their families and their doctors.



Adapted from Respiratory Medicine (2006) 100, 1952–1959

Montelukast monotherapy is a safe and effective treatment for patients suffering from asthma and allergic rhinitis.

**For the SMPC, please visit www.dafrapharma.com
and create your personal account on our website.**

ALUKON® is a prescription only drug.